Companies

NTLA · Biotech

Intellia Therapeutics, Inc.

SEC company filings

Research coverage

Classification review pending

Price Chart
Available
Reported Cash
Available
Pipeline
Scanned — no results
Catalysts
Available

Reported cash

USD 156,098,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

Next verified event · FDA target date

lonvo-z · March 10, 2027

Announced Nov 5, 2026

Official announcement
Source wording

In September, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027. Additionally, FDA advised that it is not

Drug pipeline

0 programs · 0 verified studies

Scanned — no results

10 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.